Circulating Tumor Cell Mitotic Index for Aggressive Cancer Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting and characterizing circulating tumor cells (CTCs) are limited by their rarity in circulation and inability to accurately distinguish highly aggressive cell types from less aggressive types, hindering clinical utility in cancer diagnosis and treatment.
Innovation Solution
Determine the mitotic index (MI) of CTCs by identifying their cell cycle phase, specifically through nuclear staining and morphological examination, to predict survival likelihood, grade tumors, and monitor treatment effectiveness.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If CTC enumeration is used as a prognostic indicator, then patient survival information can be obtained, but the ability to distinguish highly aggressive cell types from less aggressive cell types is insufficient
Solution Approach 1:
The patent segments the homogeneous CTC population into distinct subpopulations based on cell cycle phase (mitotic vs. non-mitotic). By dividing the CTC analysis into these functional categories, the method recovers lost prognostic information about tumor aggressiveness that cannot be obtained from simple CTC counting alone.
Solution Approach 2:
The patent applies local quality by assigning different prognostic weights to different CTC subpopulations. Mitotic CTCs are identified as having higher prognostic significance for aggressive disease, while non-mitotic CTCs represent a different risk category. This localized differentiation improves measurement precision beyond uniform CTC enumeration.
2Manufacturing precision
If CTCs are isolated using specialized filters, then detailed cellular architecture is retained, but the complexity of CTC heterogeneity and low numbers per sample inhibit clinical utility
Solution Approach 1:
The patent changes the analytical parameter from simple CTC count to mitotic index calculation. By shifting the focus to cell cycle phase assessment of filtered CTCs, the method transforms complex heterogeneity into a manageable binary classification (mitotic vs. non-mitotic), reducing analytical complexity while preserving cellular architecture details.
Solution Approach 2:
The patent extracts the mitotic figure assessment from the complex CTC analysis framework. By isolating and specifically evaluating mitotic CTCs as a separate measurable parameter, the method simplifies the overall analysis complexity while maintaining the benefits of filtered CTC isolation and detailed morphological examination.
3Loss of information
If proliferation index biomarkers are used for quantification, then CTC characterization is attempted, but the highly contested and controversial nature of PI biomarkers limits reliability
Solution Approach 1:
The patent substitutes molecular/biochemical methods (PI biomarker staining and quantification) with classical cytological methods (morphological examination of mitotic figures). This replacement eliminates the reliability issues associated with controversial proliferation index biomarkers while maintaining the ability to characterize CTC proliferation status through direct visual assessment of cell division phases.
Data Source
AI summary
Circulating tumor cells (CTCs) are associated with metastasis of malignant solid tumors in a patient. Presented here is evidence that CTCs exhibit cell cycle phase variability and that there is a strong correlation between the number of CTCs in a mitotic cell cycle phase and the prospects for long term survival of the subject from which the cells were obtained. Also presented herein are methods of determining the mitotic cell cycle phase of CTCs from a patient having cancer and using the information in grading malignant solid tumors and predicting the likelihood of survival of the patient.